Journal News

How proteolysis controls the Legionnaires’ pathogen

Inayah Entzminger
Nov. 24, 2022

Legionnaires’ disease is a severe pneumonia caused by breathing or swallowing water containing the bacterial pathogen Legionella pneumophila, which has a biphasic life cycle — a replicative phase when the bacteria are nonvirulent and a transmissive phase when they are virulent.

Researchers at the Run Ze Laboratory for Gastrointestinal Microbiome Study at Sun Yat-sen University in Guangzhou, China, have discovered that the biphasic life cycle depends on regulation of protein homeostasis by caseinolytic protease–dependent proteolysis. In their paper published in the journal Molecular & Cellular Proteomics, Zhenhuang Ge and co-authors describe how this ClpP-dependent proteolysis directly or indirectly plays a regulatory role in cellular events in L. pneumophila.

This colorized scanning electron micrograph shows a large group of Gram-negative Legionella pneumophila bacteria.
Janice Haney Carr / CDC
This colorized scanning electron micrograph shows a large group of Gram-negative Legionella pneumophila bacteria.

Ge described the team’s previous results on the physiology and pathogenesis of the ClpP protease homologue in L. pneumophila: “We found that ClpP is required for the transmission traits and cell division (and) impairs the virulence of L. pneumophila and the optimal translocation of effector proteins.”

This study continued that research, investigating the profiles of global protein abundance during replicative-to-transmissive phase transitions. During the virulence phase, approximately 330 effector proteins are translocated into host cells, triggering direct manipulation of host cell signaling pathways. However, this translocation is not simultaneous, which hints at a temporal control mechanism for the effector proteins. Ge’s team found similar temporal control mechanisms in proteomic experiments where some proteins were synthesized only during the replicative phase and not the transmissive phase.

These controls have allowed L. pneumophila to adapt to face many environments, both natural and human-made. The bacteria colonize water from 0 C to 60 C and in the pH range of 5.5 to 9.2. It can be found in water systems such as showerheads and faucets and even windshield fluid tanks of vehicles.

“(L. pneumophila) do the right things at the right time to complete the biological cycle; otherwise the disruption will have devastating consequences,” Ge explained, comparing the bacteria’s pattern to a human’s daily habits. “In the alternation of day and night, we rest at night and work during the day to ensure a healthy and long-lasting life.”

The ClpP-dependent proteolysis study directly compared protein abundances during the replicative and transmissive phases. During the replicative phase, the proteins associated with ribosome, amino sugar, nucleotide sugar and biotin metabolism pathways were enriched most significantly. These are all pathways associated with replication and growth. In contrast, during the transmissive phase, flagellar assembly proteins, signal transduction proteins, and proteins associated with microbial metabolic pathways such as propanoate and ketone body metabolism were more enriched.

When L. pneumophila cells lacked ClpP, the metabolic pathways of both the replicative and transmissive phases were disordered. The signaling alarmone ppGpp is a trigger for L. pneumophila differentiation. The expression of SpoT, an enzyme that controls the accumulation of ppGpp in response to fatty acid depletion, almost completely restored the life cycle transition of L. pneumophila, but virulence never was recovered. This demonstrated that bacterial virulence requires ClpP regulation of the effector proteins and secretion system.

“The bacterial protease ClpP, an untapped antimicrobial drug target, and the fatty acid metabolism pathway would be suitable for targeting by antibacterial drugs,” Ge concluded.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Inayah Entzminger

Inayah Entzminger is a doctoral candidate at the The Graduate Center, CUNY, in the department of biochemistry. Their research focuses on viral translation initiation mechanisms. 

Related articles

From the journals: MCP
Nivedita Uday Hegdekar
Our internal ecology
Laurel Oldach

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

The quest to treat and cure xerostomia
Interview

The quest to treat and cure xerostomia

July 23, 2024

Blake Warner, chief of the Salivary Disorders Unit at the NIH talks about his lab’s efforts to develop treatments for dry mouth.

There's more to blue cheese than just the stench
News

There's more to blue cheese than just the stench

July 21, 2024

Virginia Tech researchers discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties.

Engineering cells to broadcast their behavior can help scientists study their inner workings
News

Engineering cells to broadcast their behavior can help scientists study their inner workings

July 20, 2024

Researchers can use waves to transmit signals from the invisible processes and dynamics underlying how cells make decisions.

From the journals: JBC
Journal News

From the journals: JBC

July 19, 2024

Lung cancer cells resist ferroptosis. ORMDL3 in ulcerative colitis. Novel genetic variants in thyroid cancer. Read about these recent papers.

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision
News

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.